Systemic Anaplastic Large Cell Lymphoma

Systemic Anaplastic Large Cell Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

6 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1
Recruiting: 1
Ph III recruiting: 1
Growth YoY: —
Industry share: 100%
Top sponsor: Corvus Pharmaceuticals, Inc.
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–6 of 6 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06561048	Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma	recruiting	Phase 3	150	Corvus Pharmaceuticals, Inc.INDUSTRY	3	Sep 25, 2026	clinicaltrials
NCT00585195	A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer(PROFILE 1001)	completed	Phase 1	596	PfizerINDUSTRY	4